In the era of COVID-19, HMGB1 is considered a possible major player in the SARS-CoV-2-related triggering of hypercytokinemia, cytokine storms, and immunothrombosis, underlying the development of acute lung injury (ALI) and ARDS [12,13]. Here, HMGB1 is linked to COVID-19.